Department of Gynaecology Obstetrics, faculty of Medicine, HUG, 30 bd de la Cluse, 1211 Geneva 14, Switzerland.
Gynecol Oncol. 2010 Oct;119(1):164-6. doi: 10.1016/j.ygyno.2010.05.027. Epub 2010 Jun 30.
Ovarian cancer is the leading cause of death from gynecologic cancer in Western countries. Most of the patients are chemosensitive, and they will present a complete response after initial treatment, but most of them will relapse within 2 years. The resistance to standard chemotherapy represents a significant clinical challenge. Therefore, a better understanding of the molecular mechanisms involved in the drug resistance should allow to improve the treatment in this disease. Interestingly, recent data showed essential roles of heat shock proteins (HSPs) in various processes of carcinogenesis and their association with resistance to anticancer drugs. Here, we report the main investigations on HSPs in ovarian cancer with specific emphasis on clinical application.
卵巢癌是西方国家妇科癌症死亡的主要原因。大多数患者对化疗敏感，初始治疗后会出现完全缓解，但大多数患者会在 2 年内复发。对标准化疗的耐药性是一个重大的临床挑战。因此，更好地了解与耐药性相关的分子机制，应有助于改善这种疾病的治疗效果。有趣的是，最近的数据显示热休克蛋白（HSPs）在癌变的各个过程中发挥着重要作用，并与抗癌药物的耐药性有关。在这里，我们报告了卵巢癌中 HSPs 的主要研究结果，特别强调了其在临床应用方面的研究。
